ViewRay, Inc. (VRAY)
(Delayed Data from NSDQ)
$4.15 USD
-0.10 (-2.35%)
Updated Mar 4, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value D Growth C Momentum F VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
ViewRay (VRAY) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of -5.88% and 2.52%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
VRAYNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of -11.76% and 13.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
VRAYNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Will ViewRay (VRAY) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VRAYNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
ViewRay (VRAY) Catches Eye: Stock Jumps 7%
by Zacks Equity Research
ViewRay (VRAY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
EDAPNegative Net Change VRAYNegative Net Change
medical
ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of -12.50% and 144.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
VRAYNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.
PKINegative Net Change RMDNegative Net Change OPKNegative Net Change VRAYNegative Net Change
earnings medical
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) second-quarter results benefit from solid segmental performance.
DXCMNegative Net Change RMDNegative Net Change OPKNegative Net Change VRAYNegative Net Change
earnings medical
Masimo (MASI) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q2.
MASINegative Net Change RMDNegative Net Change OPKNegative Net Change VRAYNegative Net Change
medical
LabCorp (LH) Beats Q2 Earnings Estimates, Margins Decline
by Zacks Equity Research
LabCorp (LH) witnesses a 20.7% decline in organic volume, partially offset by acquisition volume growth of 1.2%.
RMDNegative Net Change LHNegative Net Change EXASNegative Net Change VRAYNegative Net Change
earnings medical
Ecolab (ECL) Earnings and Revenues Lag Estimates in Q2
by Zacks Equity Research
Ecolab's (ECL) second-quarter results reflect weakness in the Global Industrial and Institutional segments.
ECLNegative Net Change RMDNegative Net Change OPKNegative Net Change VRAYNegative Net Change
earnings medical
Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View
by Zacks Equity Research
Despite coronavirus-hit sales, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q2. Regulatory approvals look encouraging.
EWNegative Net Change RMDNegative Net Change EXASNegative Net Change VRAYNegative Net Change
earnings medical
Will ViewRay (VRAY) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VRAYNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Quest Diagnostics' (DGX) Q2 Earnings Beat, Volume Declines
by Zacks Equity Research
Following the guidance withdrawal last quarter, Quest Diagnostics (DGX) provides its full-year projection alongside Q2 earnings release.
DGXPositive Net Change RMDNegative Net Change EXASNegative Net Change VRAYNegative Net Change
earnings
Align Technology (ALGN) Earnings Fall Shy of Estimates in Q2
by Zacks Equity Research
Align Technology's (ALGN) segments report COVID-19-led lower sales across major geographies.
RMDNegative Net Change ALGNNegative Net Change EXASNegative Net Change VRAYNegative Net Change
earnings medical
ViewRay (VRAY) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Strength in MRIdian system business is likely to have aided ViewRay's (VRAY) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.
IARTNegative Net Change LHNegative Net Change EXASNegative Net Change VRAYNegative Net Change
medical
Neogen (NEOG) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Neogen's (NEOG) Animal Safety revenues improve in the fourth quarter on strong sales of cleaners, disinfectants and sanitizers.
RMDNegative Net Change NEOGNegative Net Change OPKNegative Net Change VRAYNegative Net Change
earnings
Thermo Fisher (TMO) Q2 Earnings Beat on COVID-19-Led Sales
by Zacks Equity Research
We are encouraged about Thermo Fisher's (TMO) exceptionally strong year-over-year revenue growth at Life Sciences Solutions segment.
RMDNegative Net Change TMONegative Net Change OPKNegative Net Change VRAYNegative Net Change
earnings medical
Intuitive Surgical (ISRG) Q2 Earnings Top Estimates, Down Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect weak performance across all businesses and lower revenues.
ISRGNegative Net Change RMDNegative Net Change OPKNegative Net Change VRAYNegative Net Change
earnings medical
Neuronetics (STIM) Looks Good: Stock Adds 11.3% in Session
by Zacks Equity Research
Neuronetics (STIM) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
VRAYNegative Net Change STIMNegative Net Change
medical
AngioDyanamics (ANGO) Reports Q4 Loss, Revenues Lag Estimates
by Zacks Equity Research
AngioDyanamics (ANGO) witnessed revenue decline across all business segments in Q4.
ANGONegative Net Change RMDNegative Net Change OPKNegative Net Change VRAYNegative Net Change
earnings medical
Abbott (ABT) Q2 Earnings Top, Coronavirus Test Sales Solid
by Zacks Equity Research
Abbott (ABT) Q2 earnings reflect healthy growth within its Diabetes Care business and encouraging coronavirus test sales.
RMDNegative Net Change ABTNegative Net Change OPKNegative Net Change VRAYNegative Net Change
earnings medical
Medical Instruments Outlook Dull Amid Coronavirus Crisis
by Urmimala Biswas
Many sub domains within the medical instrument space are bearing the brunt of the coronavirus-led prolonged stay-at-home orders.
VRAYNegative Net Change VARNegative Net Change TMONegative Net Change IDXXNegative Net Change IARTNegative Net Change EWNegative Net Change ABMDNegative Net Change
medical
The Zacks Analyst Blog Highlights: Domo, ViewRay, Commercial Metals, Clearwater Paper and Momenta Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Domo, ViewRay, Commercial Metals, Clearwater Paper and Momenta Pharmaceuticals
MNTAPositive Net Change CLWNegative Net Change CMCNegative Net Change VRAYNegative Net Change DOMONegative Net Change
medical
5 Top Momentum Stocks of June Amid Resurgence of Coronavirus
by Nalak Das
Despite market's roller-coaster ride, a handful of momentum stocks with a favorable Zacks Rank have provided double-digit returns so far in June.
MNTAPositive Net Change CLWNegative Net Change CMCNegative Net Change VRAYNegative Net Change DOMONegative Net Change
basic-materials biotechs internet medical
Top Ranked Momentum Stocks to Buy for June 23rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 23rd
ZUONegative Net Change VRAYNegative Net Change SNBRNegative Net Change HEARNegative Net Change
cloud-computing consumer-discretionary internet medical